Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.39 |
| ▸ | MET | P08581 | 3/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15262237 | 0.91 | PLA2G7 (0.42) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL9904935 | 0.90 | PLA2G7 (0.40) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL9904792 | 0.85 | MET (0.39) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL9905827 | 0.82 | GRIN2B (0.37) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL15266768 | 0.80 | CSF1R (0.38) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL9905066 | 0.77 | P2RX7 (0.41) | PLA2G7P2RX7ALKBH1 | |
| SCHEMBL9905127 | 0.77 | PLA2G7 (0.41) | PLA2G7GRIN2BGRIN1 | |
| SCHEMBL9905081 | 0.75 | MAOB (0.40) | PLA2G7P2RX7 | |
| SCHEMBL9923532 | 0.73 | CSF1R (0.35) | CSF1RMETPDGFRBPDGFRAFLT3 | |
| SCHEMBL9900548 | 0.73 | MAOA (0.39) | PLA2G7GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| EP-2649050-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012075917-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252986-A1 | COMPOUNDS | LIPG, ENPP2, PLA2G1B | CSF1R 1759/4885MET 4796/4885PDGFRB 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.